ADVM
NASDAQ
$4.36
Adverum Biotechnologies Inc (ADVM)
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops candidate gene therapy products to treat eye and rare diseases. The company is headquartered in Redwood City, California.
Sector:
Healthcare
Industry:
Biotechnology
Target: $4.88 (+11.81%)
Market Cap
$102M
P/B Ratio
0.93
Beta (5Y)
1.06
Price Chart
Valuation
Market Cap$102M
P/S94.37
P/B0.93
Profitability
Gross Profit (TTM)-$77M
EBITDA-$189M
EPS-$8.17
Growth & Risk
EPS 5Y CAGR-8.32%
FCF 5Y CAGR+8.83%
Beta (5Y)1.06
Sharpe Ratio1.36